Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?

Journal of Nephrology

Volumn 15, Issue 5, 2002, Pages 480-488

  Galli, Giovanni ^a   Panzetta, Giovanni ^a  

^a UO Nefrologia e Dialisi   (Italy)

Author keywords

Acute renal failure; COX isoforms; COX 2 inhibitors; Cyclooxygenase (COX); Nephrotoxicity; Non steroidal anti inflammatory drugs (NSAID); Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CLONIDINE; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDOMETACIN; KETOROLAC; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RENIN; ROFECOXIB; SODIUM; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; AGED; ANKLE EDEMA; ARTHRITIS; BARTTER SYNDROME; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIURESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; EOSINOPHILIA; EOSINOPHILURIA; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY PAPILLA NECROSIS; KIDNEY PERFUSION; KIDNEY TUMOR; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTOXICITY; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEINURIA; RENIN RELEASE; REVIEW; SODIUM URINE LEVEL; TISSUE INJURY; VASOCONSTRICTION; VASODILATATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0036759810     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React 1998; 20: 3-15.
2. Henrich WL. Nephrotoxicity of non-steroidal anti-inflammatory agents. In Schrier R, Gottshalk C, Eds. Diseases of the Kidney (5th edn.). Boston: Little Brown 1201-18.
3. 2 effects on adrenergic transmission in the kidney of the anesthetized dog. J Pharmacol Exp Ther 1981; 218: 588-92.
4. Dunn MJ, Zambrask E. Renal effects of drugs that inhibit prostaglandins synthesis. Kidney Int 1980; 18: 609-17.
5. Cronin RE, Henrich WI. Toxic nephropaties. In Brenner BM Ed. Brenner & Rector's the Kidney (6th edn.). Philadelphia: W.B. Saunders Company 2000; 1563-96.
6. Ichicawa I, Brenner BM. Importance of efferent arteriolar vascular tone in regulation of proximal tubular fluid reabsorption and glomerulotubular balance in the rat. J Clin Invest 1980; 65: 1192.
7. Higashihara E, Stokes JB, Kokko JP. Cortical and papillary micro-puncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production. J Clin Invest 1979; 64: 1277-87.
8. Iino Y, Imai M. Effects of prostaglandins on Na transport in isolated collecting tubules. Pflügers Arch 1978; 373: 125-33.
9. Roman RJ, Kauker ML. Renal effect of prostaglandin synthetase inhibition in rats: Micropuncture studies. Am J Physiol 1978; 235 (Renal Fluid Electrolyte Physiol 4): F111-8.
10. 2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977; 49: 1099-104.
11. Work J, Baehler TR, Kotchen A. Effect of prostaglandin inhibition on sodium chloride reabsorption in the diluting segment of the conscious dog. Kidney Int 1980; 17: 24-30.
12. Dunn MJ, Hood VI. Prostaglandins and the kidney. Am J Physiol 1977; 233: F169.
13. Dunn MJ, Zambraski E. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int 1980; 18: 609-22.
14. Henrich WL, Campbell WB. Relationship between prostaglandins and the β-adrenergic pathway to renin secretion. An in vitro study. Am J Physiol 1984; 247: E343-8.
15. Henrich WL. Prostaglandins in renin secretion. Kidney Int 1981; 19: 822-30.
16. Fong HJ, Cohen AH. Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982; 2: 28.
17. Whelton A, Stout RL, Spilman PS. Renal effects of ibuprofen, piroxicam and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990; 112: 568-76.
18. Marasco WA, Gikas PW, Aziz-Baumgartner R. Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkaliemia, tubular necrosis, proteinuria. Arch Intern Med 1987; 147: 2107-16.
19. Segasothy M, Samad SA, Zulfiquar A, Bennet WM. Renal dysfunction and renal papillary necrosis with long term use of NSAIDs as a sole or predominant analgesic: A new form of analgesic nephropathy. J Am Soc Nephrol 1993; 4: 759.
20. Torres VE. Present and future of the nonsteroidal antiinflammatory drugs in nephrology. Mayo Clin Proc 1982; 57: 389-93.
21. Morgenstern SJ, Burns FJ, Fraley DS. Ibuprofen-associated lipid nephrosis without interstitial nephritis. Am J Kidney Dis 1989; 16: 50-2.
22. Falk RJ, Jennette JC, Nachman PH. Primary glomerular disease. In Brenner BM Ed. Brenner & Rector's the Kidney (6th edn.). Philadelphia: W.B. Saunders Company, 2000; 1263-349.
23. Ravskov U. Glomerular, tubular and interstitial nephritis associated with nonsteroidal anti-inflammatory drugs. Evidence of common mechanism. Br J Clin Pharmacol 1999; 47: 203-10.
24. Nies AS, Gal J, Fadul S. Indomethacin-furosemide interaction: The importance of renal blood flow. J Pharmacol Exp Ther 1983; 226: 27-32.
25. Seelig CB, Maloney PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J 1990; 83: 1144.
26. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40.
27. Otto JC, Smith WL. Prostaglandin endoperoxide synthases-1 and -2. J Lipid Mediators Cell Signalling 1995; 12: 139-56.
28. Siegle I, Klein T, Bakman JT. Expression of COX-1 and COX-2 in human synovial tissue: Differential elevation of COX-2 in inflammatory joint disease. Arthritis Rheum 1998; 41: 122-9.
29. Massy ZA, Swan SK. Cyclooxygenase-2 and atherosclerosis: Friend or foe? Nephrol Dial Transplant 2001; 16: 2286-9.
30. 2 formation in tissue from human colonic mucosa and chronic bursitis. Gastroenterology 1998; 114: A139.
31. Richards JS. Sounding the alarm: Does induction of the prostaglandin endoperoxide synthase-2 control the mammalian ovulatory clock? Endocrinology 1997; 138: 4047-8.
32. Forwood MR. Inducible cyclo-oxigenase (COX 2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 1997; 12: 1198-203.
33. Sorli CH. Basal expression of the cyclo-oxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci USA 1998; 95: 1788-93.
34. Ermert A. Cyclo-oxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol 1998; 18: 479-88.
35. Lukiw WJ, Bazan NG. COX-2 RNA message abundance, stability and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997; 50: 937-45.
36. Bishop-Bailey D. Induction of cyclo-oxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 1997; 17: 1644-8.
37. Gilroy DW, Colville-Nash PR, Willis B, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.
38. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355: 646-8.
39. Kramer BK. Cyclo-oxygenase-2 and renal function. Nephrol Dial Transplant 2001; 16: 180-3.
40. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and -2 in human tissues. FEBS Lett 1993; 330: 156-60.
41. Feng L, Xia Y, Tang W, Hwang D, Wilson C. Expression of cyclooxygenase (COX)-1, COX-2, and cytosolic phospholipase A2 (cPLA2) in anti-GBM antibody (Ab) glomerulonephritis (GN). J Am Soc Nephrol 1993; 4: A452.
42. Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000; 11: 2394-400.
43. Kömhoff M, Gröne HJ, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997; 272: F460-8.
44. Schneider A, Wolf G, Reszka M, Thaiss F, Helmchen U, Stahl RA. Cyclooxygenase-2 inhibition enhances glomerular mesangial cell proliferation in a rat model of renal ablation. (abstr.) J Am Soc Nephrol 1997; S605.
45. Schneider A, Stahl RA. Cyclooxygenase-2 (COX-2) and the kidney: Current status and potential perspectives. Nephrol Dial Transplant 1998; 13: 10-2.
46. Harris CR. Macula densa signalling - A potential role of cyclooxygenase-2 (COX-2)? Nephrol Dial Transplant 1998; 15: 1504-6.
47. Chanmugam P, Feng L, Liou S, Jang BC, Boudreau M, Yu G, Lee JH, Kwon HJ, Beppu T, Yoshida M, Xia Y, Wilson CB, Hwang D. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis. J Biol Chem 1995; 270: 5418-26.
48. Schneider A, Harendza S, Zahner G, Jocks T, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RA. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int 1999; 55: 430-41.
49. Salvemini D, Seibert K, Masferrer JL, Seibert K, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994; 93: 1940-7.
50. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35: 937-40.
51. Australian Adverse Drug Reactions Bulletin 2000; 19, 2.
52. Wolf G, Porth J, Stahl RA. Acute renal failure associated with rofecoxib. Ann Intern Med 2000; 133: 394.
53. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999; 457: 475-7.
54. Khan KN, Burke A, Stanfield MK, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001; 23: 321-30.
55. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001; 38, 6: 1145-57.
56. Daniels B, Gertz B, Morrison B, Seidenberg B. Renal safety profile of Rofecoxib, a specific inhibitor of COX-2, in controlled clinical trials (abstr.) Arthritis Rheum 1999; 42 (suppl 9): S 143.
57. Stahl RA. Non-steroidal anti-inflammatory agents in patients with a renal transplant. Nephrol Dial Transplant 1998; 13: 1119-21.
58. Galli G, Panzetta G. Caso clinico: Insufficienza renale acuta reversible sia da FANS non selettivo (ketorolac) sia da COX-2 inibitore (celecoxib) nello stesso soggetto. G Ital Nefrol 2002; 19: 199-203.
59. Stubanus M, Riegger GA, Kammerl MC, Fischereder M, Krämer BK. Renal side-effects of cyclo-oxygenase-type-2 inhibitor use. Lancet 2000; 355: 753.
60. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA. Effects of specific inhibition of cyclo-oxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. JPET 1999; 289: 735-41.
61. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JL, Musliner TA, Gertz BJ, Brater DC, Yao SL. Effect of cyclo-oxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.
62. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis GS. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-70.
63. Whelton A, Brater DC, Sica DA, Verburg KM, Drower EJ, Geis GS. Effects of celecoxib and naproxen on renal function in chronic renal insufficiency patients. J Am Soc Nephrol 1999; 10: 92A (abstr).
64. Simon LS, Weaver AL, Graham DY. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999; 282: 1921-8.
65. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor. Am J Ther 2000; 7: 159-75.
66. Slater DM, Berger LC, Newton R, Moore GE, Bennet PR. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 1995; 172: 77-82.
67. Zhang MZ, Wang JL, Cheng HF, Harris RC, McKanna JA. Cyclooxygenase-2 in rat nephron development. Am J Physiol 1997; 273: F994-1002.
68. Balasubramaniam J. Selective COX-2 inhibitors and nephrotoxicity. Am J Kidney Dis 2000; 36: 675-6.
69. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Lancet 1999; 354: 1615.
70. Kömhoff M, Seyberth HW, Nüsing RM, Breyer MD. Cyclooxygenase-2 expression is associated with the macula densa in kidneys from patients with Barter like syndrome (abstr). J Am Soc Nephrol 1999; 10: 437A.
71. Schnermann J. Cyclooxygenase-2 and macula densa control of renin secretion. Nephrol Dial Transplant 2001; 16: 1735-8.
72. Breyer MD. COX-2 selective NSAIDs and renal function: Gain without pain? Kidney Int 1999; 55: 738-9.
73. Wang J-L, Cheng H-F, Shappel S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334-42.
74. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001; 107: 889-98.
75. Wang J-L, Cheng H-F, Shappel S, Harris RC. Cyclooxygenase-2 (COX-2) inhibition decreases proteinuria in a hypertensive diabetic model (abstr). J Am Soc Nephrol 1999; 10: 3505A.
76. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg M, Kvien TK, and Schnitzer TJ for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.